Thrombus Treatment Market Size was valued at USD 39.43 Billion in 2023. The Global Thrombus Treatment industry is projected to grow from USD 40.27 Billion in 2024 to USD 70.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.57% during the forecast period (2024 - 2032).
The factors influencing the market growth are increasing incidence of trauma cases and rising adoption of sedentary lifestyle are bolstering the market growth.
Trauma is considered as one of the most common causes for the formation of thrombus in the lower extremities. When any blood vessels get damages, the surround blood thickens and forms a clot. Hence, blood vessel damage due to trauma can cause the formation of a thrombus. The increases number trauma cases, especially road accidents have led to the increase in demand for thrombus treatment. According to the WHO in June 2022, around 1.3 million people lose their lives due to road accidents globally. Additionally, 20-30 trillion people suffer non-fatal injuries per year. Over 90% of such fatalities occur in low- and middle-income countries which is expected to drive the market of thrombus treatment significantly in those countries with a significant growth rate.
Additionally, there were 178 million new fracture cases registered in 2019 globally which had increased by 33.4% since 1990. The total prevalence of acute and long-term fracture symptoms had reached 455 million in 2910 with an increase of 67.5% since 1990. Fracture is another common cause for thrombosis. Hence, the increasing incidence of trauma cases is driving market demand for the Thrombus Treatment.
The market segments of thrombus treatment, based on type, includes atrial thrombus and venous thrombus. The atrial thrombus bifurcated into right atrial thrombus and left atrial thrombus. Venous thrombus held the largest market share and contributed USD 22.58 billion in 2021 owing to the interaction between obesity and other risk factors doubles the risk of venous thrombus. The World Obesity Atlas 2022 stated that 1 billion people globally i.e., 1 in 5 women and 1 in 7 men will have diabetes by 2030. Therefore, the increase in obesity in the coming years will lead to venous thrombosis, fueling the venous thrombosis segment market.
The Thrombus Treatment Market data has been segmented, based on treatment, by medical therapy, surgery, and others. The medical therapy segment has been segmented into antiplatelets, anticoagulants, and thrombolytics. Medical therapy held the largest market share and contributed USD 34.36 billion in 2021 and the surgery anticipated to register the highest CAGR of 7.78% from 2024 to 2032. The most common antiplatelets used to treat thrombus include acetylsalicylic acid (ASA), clopidogrel, prasugrel, and ticagrelor. Acetylsalicylic acid includes aspirin, which is effective in treating thrombosis.
December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO.
Figure 2: Thrombus Treatment Market, by Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America held the largest market share and contributed USD 16.19 billion in 2021 owing to developed healthcare infrastructure, research grants for producing safe and effective thrombus treatment, the growing aged and obese population in the region. For instance, according to the World Health Organization (WHO) 2021, the North America population over 80 years will triple from 143 million in 2019 to 426 million in 2050. Therefore, the growing aged and obese population supports the market growth of thrombus treatment.
Further, the major countries studied are: The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: THROMBUS TREATMENT MARKET BY REGION 2022 & 2032
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe thrombus treatment market accounts for the second-largest market share owing to growing research and treatment of deep-vein thrombosis and growing awareness regarding thrombus complications are the major factors driving the market growth in Europe. For instance, according to the article published in National Center for Biotechnology Information (NCBI), deep vein thrombosis (DVT) is a healthcare burden in Europe. Furthermore, the Germany market of thrombus treatment held the largest market share, and the UK market of thrombus treatment is the fastest growing market in the Europe region.
The Asia-Pacific thrombus treatment market is expected to grow at a significant share from 2024 to 2032. Owing to the presence of a diversified patient pool, the rising prevalence of deep vein thrombosis, and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as China and India are likely to boost the market in the Asia-Pacific region. Moreover, China market of thrombus treatment held the largest market share, and the India market of thrombus treatment is the fastest growing market in the Asia-Pacific region.
Major market players are spending a lot of money on R&D to increase their product lines, which will help the thrombus treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the thrombus treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Teva Pharmaceutical Industries Ltd. (Israel) is one of the leaders in the pharmaceutical industry engaged in developing and providing services for generic medicines. The company utilizes its arrangement of more than 1,800 molecules to create a wide variety of generic products in almost every therapeutic area. It specializes in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics. In June 2022, the company launched a generic version of apixaban oral anticoagulant that directly inhibits factor X, in UK.
Thrombus Treatment Industry Developments
December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO.
In April 2021, The US Food and Drug Administration has granted AngioDynamics, Inc. (US) 510(k) clearance for its AlphaVac mechanical thrombectomy system. This allows for precise control of clot removal while minimizing patient blood loss. It has expanded the company's thrombus management portfolio, allowing it to serve the thrombectomy market.
April 2018, Bristol-Myers Squibb Company (US) collaborated with Janssen Pharmaceuticals, Inc. (Belgium) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of BMS-986177, an investigational anticoagulant compound being studied for the prevention and treatment of major thrombotic conditions.
North America
Europe
Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 39.43 billion |
| Market Size 2024 | USD 40.27 billion |
| Market Size 2032 | USD 70.54 billion |
| Compound Annual Growth Rate (CAGR) | 6.57% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2018 & 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), Bayer AG (Germany) and others |
| Key Market Opportunities | ·      New product approvals and launches |
| Key Market Drivers | ·      Increasing incidence of trauma cases ·      Rising adoption of sedentary lifestyle |
Thrombus Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Thrombus Treatment Market is anticipated to reach 70.54 billion at a CAGR of 6.57% during the forecast period of 2024-2032.
The US is expected to hold a 73.52% share of the global market for thrombus treatment market during the forecast period of 2024-2032.
The thrombus treatment market is expected to grow at a 6.57% CAGR during the forecast period from 2024 to 2032.
The North America region market held the largest market share in thrombus treatment market.
The key players include Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), Bayer AG (Germany) and others.
The venous thrombus segment led the thrombus treatment market.
Medical therapy segment had the largest market in 2021 with market share over 58.30%.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
